Archives
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
Distinct Pathways in Penile Urethral Development: Insights f
2026-07-30
This study provides a comparative analysis of penile development in guinea pigs and mice, revealing that distinct patterns of Shh, Fgf10, and Fgfr2 expression underlie species-specific differences in urethral groove and prepuce formation. The findings offer new mechanistic insights relevant for developmental biology and teratogenicity research.
-
Spliceosome Acetylation Alters PARP Inhibitor Sensitivity in
2026-07-30
This study reveals that acetylation-dependent regulation of the spliceosome core component SmD2 modulates alternative splicing and DNA repair in hepatocellular carcinoma (HCC). The findings provide a mechanistic rationale for combining PARP inhibitors with HDAC inhibition in HCC, offering new opportunities for targeting DNA repair deficiencies beyond BRCA-mutant tumors.
-
PF-573228: Potent FAK Inhibitor for Mechanotransduction and
2026-07-29
PF-573228 is an ATP-competitive FAK inhibitor with nanomolar potency, enabling precise interrogation of FAK signaling in cancer and tissue engineering. This dossier outlines its mechanism, benchmarks, and practical limits for anti-angiogenic and cell migration research.
-
Ganetespib (STA-9090): Precision Hsp90 Inhibition in Advance
2026-07-29
Discover how Ganetespib (STA-9090) redefines Hsp90 inhibition for cancer research, offering unique mechanistic insights and practical assay guidance. This article delivers a fresh, scientifically rigorous perspective that goes beyond current literature.
-
Dehydroabietic Acid: Dual PPAR-α/γ Agonist for Metabolic Res
2026-07-28
Dehydroabietic acid is a high-purity, dual PPAR-α/γ agonist that modulates lipid metabolism and insulin sensitivity. This compound, available from APExBIO, is validated for advanced metabolic disorder research and features robust solubility in DMSO and ethanol. Its precise action and stringent quality controls make it ideal for reproducible experimental design.
-
IWP-2: Advanced Wnt Production Inhibitor Protocols for Cance
2026-07-28
IWP-2, a potent Wnt production inhibitor from APExBIO, empowers researchers to precisely disrupt Wnt/β-catenin signaling in cancer, tissue engineering, and cell culture paradigms. This guide unpacks actionable workflows, troubleshooting strategies, and cross-domain insights for leveraging IWP-2 in high-impact experimental systems.
-
Escitalopram in Experimental Psychiatry: From Molecular Sele
2026-07-27
Explore Escitalopram's unique selectivity and translational value in antidepressant research. This article goes beyond protocol basics, revealing assay design nuances and the real-world impact of recent clinical findings.
-
PF-573228: Precision FAK Inhibition for Mechanotransduction
2026-07-27
Explore how PF-573228, a potent FAK inhibitor, enables advanced interrogation of mechanotransduction and cell signaling in cancer and tissue engineering. This article uniquely dissects assay design and practical insights, making it indispensable for researchers seeking reliable, translational protocols.
-
PF-562271 HCl: Selective FAK/Pyk2 Inhibition in Cancer Resea
2026-07-26
PF-562271 HCl is a potent, reversible FAK/Pyk2 inhibitor with nanomolar selectivity, widely used to study tumor growth inhibition and focal adhesion kinase signaling pathways. Evidence demonstrates its ability to suppress FAK phosphorylation and impede tumor proliferation in preclinical models. This dossier details its mechanism, evidence base, and integration into cancer research workflows.
-
Biotin-HPDP: Precision Thiol-Specific Protein Labeling Insig
2026-07-25
Unlock the full potential of Biotin-HPDP for thiol-specific, reversible protein labeling, with stepwise workflow enhancements and troubleshooting strategies. Discover how recent advances in S-palmitoylation detection and redox proteomics are powered by this versatile reagent, as validated by APExBIO's data-backed protocols.
-
Itraconazole: Optimizing Triazole Antifungal Workflows in Ca
2026-07-24
Itraconazole’s dual utility as a triazole antifungal agent and a CYP3A4 interaction tool enables advanced dissection of Candida biofilm resistance and autophagy-driven drug resistance. This guide delivers actionable experimental protocols, data-backed troubleshooting, and insights from recent breakthroughs—empowering researchers to maximize translational impact using APExBIO’s validated compound.
-
Imidazoles Target AdhE in Cryptosporidium parvum: Screening
2026-07-24
A recent study identified antifungal imidazoles as potent, selective inhibitors of the bifunctional aldehyde/alcohol dehydrogenase (AdhE) in Cryptosporidium parvum, a key pathogen in diarrheal disease. This work demonstrates both a novel drug target and proof-of-concept for repurposing imidazoles, providing a framework for high-throughput anti-cryptosporidial drug discovery.
-
Tivozanib (AV-951): Optimizing VEGFR Inhibition in Oncology
2026-07-23
Tivozanib (AV-951) stands apart as a potent, selective VEGFR inhibitor for advanced anti-angiogenic oncology workflows. Leveraging its sub-nanomolar efficacy and reproducibility, researchers can achieve precise pathway inhibition and robust data in renal cell carcinoma and solid tumor models.
-
IWP-2 as a Wnt Production Inhibitor: Protocols and Pitfalls
2026-07-23
IWP-2, a potent Wnt production inhibitor from APExBIO, empowers researchers to dissect Wnt/β-catenin signaling with precision, especially in cancer and neurodevelopmental models. This guide delivers actionable workflows, troubleshooting strategies, and cross-domain insights, bridging bench science with translational potential.
-
Foretinib (GSK1363089): Optimizing Tumor Cell Growth Inhibit
2026-07-22
Foretinib (GSK1363089) empowers cancer researchers with robust, multi-kinase inhibition, streamlining workflows for dissecting tumor growth, motility, and metastasis. Discover best-in-class protocol enhancements, troubleshooting strategies, and actionable insights—guided by recent advances in drug response evaluation.